Patients with m Clear
mRCC and no prior
therapy
Intermediate-poor
prognosis disease (IC)
Stratification:
Intermediate vs poor
Bone mets yes or no
CABOZANTINIB
79 pts
SUNITINIB
78 pts
Treat until PD,
unacceptable
toxicity or
discontinuation
for any other
reason
ESMO 2016
: CABOSUN: Randomized phase II Sunitinib
vs
Cabozantinib
1:1
R
A
N
D
O
M
I
Z
A
T
I
O
N
